NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]

NCT00700258

CompletedN/A

Sponsor: Pfizer

Conditions: Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors

Interventions: Temsirolimus, Temsirolimus, Sunitinib, Sunitinib, Axitinib

Countries: Germany

The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent / refractory mantle cell lymphoma (MCL) and gastro-intestinal stroma tumors (GIST) under the conditions of routine use

Eligibility overview

Sex: ALL

Age: 18 Years to 99 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients with proven tumor of RCC, MCL or GIST by histology.
* Informed consent signed by patient.

Exclusion Criteria:

* Pregnancy

Locations (77)

Ulm, Baden-Wurttemberg, Germany
Neumünster, Schleswig-Holstein, Germany
Ahaus, Germany
Amberg, Germany
Aschaffenburg, Germany
Aschaffenburg, Germany
Bautzen, Germany
Bayreuth, Germany
Berlin, Germany
Bernburg, Germany
Chemnitz, Germany
Chemnitz, Germany
Chemnitz, Germany
Chemnitz, Germany
Cologne, Germany
Cologne, Germany
Deggendorf, Germany
Dessau, Germany
Dresden, Germany
Dresden, Germany
Eisleben Lutherstadt, Germany
Erfurt, Germany
Erlangen, Germany
Frankfurt am Main, Germany
Frankfurt am Main, Germany
Fulda, Germany
Göttingen, Germany
Greifswald, Germany
Güstrow, Germany
Hamburg, Germany
+ 47 more on CT.gov